Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 2/20 | 0.36 |
| ▸ | MC5R | P33032 | 2/20 | 0.36 |
| ▸ | MC3R | P41968 | 1/20 | 0.36 |
| ▸ | IL6 | P05231 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 2/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12061652 | 0.93 | MC4R (0.37) | MC4RMC5RMC3RIL6TLR7 | |
| SCHEMBL15787201 | 0.85 | MC4R (0.39) | MC4RMC5RMC3RIL6TLR7 | |
| SCHEMBL12075420 | 0.84 | MC4R (0.38) | MC4RMC5RMC3RIL6TLR7 | |
| SCHEMBL17484492 | 0.83 | MC4R (0.39) | MC4RMC5RMC3RIL6TLR7 | |
| SCHEMBL20082571 | 0.83 | CCR6 (0.36) | MC4RMC5RMC3R | |
| SCHEMBL13822 | 0.82 | MC4R (0.38) | MC4RMC5RMC3RIL6TLR7 | |
| SCHEMBL13742 | 0.82 | EP300 (0.40) | MC4RMC5RMC3REP300 | |
| SCHEMBL12061484 | 0.82 | HDAC1 (0.33) | — | |
| SCHEMBL15785010 | 0.82 | HDAC1 (0.33) | PARP1 | |
| SCHEMBL12075768 | 0.82 | MC4R (0.38) | MC4RMC5RMC3RIL6TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2011047319-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | MC4R 2989/4885MC5R 3036/4885MC3R 3163/4885 |
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | MC4R 2989/4885MC5R 3036/4885MC3R 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.